Multidisciplinary Association for Psychedelic Studies

The Multidisciplinary Association for Psychedelic Studies (MAPS), founded in 1986, is a 501(c)(3) nonprofit research and educational organization that has raised over $140 million for psychedelic research and education. MAPS has incubated Lykos Therapeutics, a drug-development public benefit company, and The Zendo Project, a leader in psychedelic harm reduction. The organization has completed two observational studies on the long-term effects of ibogaine treatment in Mexico and New Zealand and sponsors the world’s most advanced psychedelic-assisted therapy research. MAPS advocates for the dignity and rights of all people who use drugs, free from fear and stigma, and has developed a diverse network of clinics and therapists to ensure cost is not a barrier to psychedelic treatment. They have awarded $410,000 in tuition scholarships to over 100 trainees, prioritizing Black, Indigenous, and practitioners of color. MAPS has hosted the largest gathering of the Psychedelic Renaissance and aims to end drug prohibition globally, unlocking the healing potential of psychedelics for all who seek their benefit. The organization envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses. MAPS has earned the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator. They have partnered with the City and County of Denver to provide psychedelic crisis assessment and intervention training to first responders and announced the Psychedelic Science 2025 Conference, the largest psychedelic conference in history, to be held in Denver, Colorado. MAPS has reintroduced its Fiscal Sponsorship Program to support grassroots organizations in the psychedelic movement and has submitted a New Drug Application to the FDA for MDMA-assisted therapy for PTSD. They have published results from the first study of LSD therapy in over 40 years and conducted the first double-blind, placebo-controlled study of the therapeutic use of LSD in human beings since the early 1970s. MAPS has also completed enrollment for its second Phase 3 trial of MDMA-assisted therapy for PTSD.